Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.
Raltegravir is an HIV integrase inhibitor that is metabolized through glucuronidation by uridine diphosphate glucuronosyltransferase 1A1, and its use is anticipated in combination with atazanavir (a uridine diphosphate glucuronosyltransferase 1A1 inhibitor). Two pharmacokinetic studies of healthy subjects assessed the effect of multiple-dose atazanavir or ritonavir-boosted atazanavir on raltegravir levels in plasma. Atazanavir and atazanavir plus ritonavir modestly increase plasma levels of raltegravir.
Iwamoto
Marian
M
Merck, Whitehouse Station, RY34-A500, PO Box 2000, Rahway, NJ 07065-0900, USA. marian_iwamoto@merck.com
Wenning
Larissa A
LA
Mistry
Goutam C
GC
Petry
Amelia S
AS
Liou
Sarah Y
SY
Ghosh
Kaylan
K
Breidinger
Sheila
S
Azrolan
Neal
N
Gutierrez
Maria J
MJ
Bridson
William E
WE
Stone
Julie A
JA
Gottesdiener
Keith M
KM
Wagner
John A
JA
D000328:Adult; D019380:Anti-HIV Agents / Q000493:pharmacokinetics*; D000069446:Atazanavir Sulfate; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009842:Oligopeptides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D009930:Organic Chemicals / Q000008:administration & dosage / Q000493:pharmacokinetics*; D010919:Placebos / Q000008:administration & dosage; D010949:Plasma / Q000737:chemistry*; D011725:Pyridines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium
D019380:Anti-HIV Agents; D009842:Oligopeptides; D009930:Organic Chemicals; D010919:Placebos; D011725:Pyridines; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D000069446:Atazanavir Sulfate